Hipogonadismo em homens

Referências

Principais artigos

Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018 Aug;200(2):423-32.Texto completo  Resumo

Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.Texto completo  Resumo

Matsumoto AM. Diagnosis and evaluation of hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):47-62. Resumo

Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.Texto completo  Resumo

European Association of Urology. EAU guidelines on sexual and reproductive health. 2024 [internet publication].Texto completo

Artigos de referência

1. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018 Aug;200(2):423-32.Texto completo  Resumo

2. Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.Texto completo  Resumo

3. Salonia A, Rastrelli G, Hackett G, et al. Paediatric and adult-onset male hypogonadism. Nat Rev Dis Primers. 2019 May 30;5(1):38.Texto completo  Resumo

4. Sharma A, Jayasena CN, Dhillo WS. Regulation of the hypothalamic-pituitary-testicular axis: pathophysiology of hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):29-45. Resumo

5. Tajar A, Forti G, O'Neill TW, et al; EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European male ageing study. J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8. Resumo

6. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010 Jul 8;363(2):123-35.Texto completo  Resumo

7. Matsumoto AM. Diagnosis and evaluation of hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):47-62. Resumo

8. Dwyer AA, Smith N, Quinton R. Psychological aspects of congenital hypogonadotropic hypogonadism. Front Endocrinol (Lausanne). 2019 Jul 5;10:353.Texto completo  Resumo

9. Thirumalai A, Anawalt BD. Epidemiology of male hypogonadism. Endocrinol Metab Clin North Am. 2022 Mar;51(1):1-27.Texto completo  Resumo

10. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007 Nov;92(11):4241-7.Texto completo  Resumo

11. Lee DM, Pye SR, Tajar A, et al. Cohort profile: the European Male Ageing Study. Int J Epidemiol. 2013 Apr;42(2):391-401.Texto completo  Resumo

12. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008 Jul;93(7):2737-45.Texto completo  Resumo

13. Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012 May;97(5):1508-16.Texto completo  Resumo

14. Cheng J, Han B, Li Q, et al. Testosterone: relationships with metabolic disorders in men-an observational study from SPECT-China. Int J Endocrinol. 2017;2017:4547658.Texto completo  Resumo

15. Groth KA, Skakkebæk A, Høst C, et al. Clinical review: Klinefelter syndrome - a clinical update. J Clin Endocrinol Metab. 2013 Jan;98(1):20-30.Texto completo  Resumo

16. Gravholt CH, Chang S, Wallentin M, et al. Klinefelter syndrome: integrating genetics, neuropsychology, and endocrinology. Endocr Rev. 2018 Aug 1;39(4):389-423.Texto completo  Resumo

17. Delessard M, Saulnier J, Rives A, et al. Exposure to chemotherapy during childhood or adulthood and consequences on spermatogenesis and male fertility. Int J Mol Sci. 2020 Feb 20;21(4):1454.Texto completo  Resumo

18. Chiba K, Ramasamy R, Lamb DJ, et al. The varicocele: diagnostic dilemmas, therapeutic challenges and future perspectives. Asian J Androl. 2016 Mar-Apr;18(2):276-81.Texto completo  Resumo

19. Thornton CA. Myotonic dystrophy. Neurol Clin. 2014 Aug;32(3):705-19, viii. Resumo

20. Arnold FJ, Merry DE. Molecular mechanisms and therapeutics for SBMA/Kennedy's disease. Neurotherapeutics. 2019 Oct;16(4):928-47.Texto completo  Resumo

21. Roychoudhury S, Chakraborty S, Choudhury AP, et al. Environmental factors-induced oxidative stress: hormonal and molecular pathway disruptions in hypogonadism and erectile dysfunction. Antioxidants (Basel). 2021 May 24;10(6):837.Texto completo  Resumo

22. Duca Y, Aversa A, Condorelli RA, et al. Substance abuse and male hypogonadism. J Clin Med. 2019 May 22;8(5):732.Texto completo  Resumo

23. Claahsen-van der Grinten HL, Stikkelbroeck N, Falhammar H, et al. Management of endocrine disease: gonadal dysfunction in congenital adrenal hyperplasia. Eur J Endocrinol. 2021 Mar;184(3):R85-97. Resumo

24. Fang Q, George AS, Brinkmeier ML, et al. Genetics of combined pituitary hormone deficiency: roadmap into the genome era. Endocr Rev. 2016 Dec;37(6):636-75.Texto completo  Resumo

25. Kiserud CE, Fosså A, Bjøro T, et al. Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer. 2009 Feb 10;100(3):455-63.Texto completo  Resumo

26. Luton JP, Thieblot P, Valcke JC, et al. Reversible gonadotropin deficiency in male Cushing's disease. J Clin Endocrinol Metab. 1977 Sep;45(3):488-95. Resumo

27. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male. 2015 Mar;18(1):5-15.Texto completo  Resumo

28. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol. 2008 Nov;159(5):507-14.Texto completo  Resumo

29. Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011 Jul;34(7):1669-75.Texto completo  Resumo

30. Dhindsa S, Ghanim H, Batra M, et al. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018 Jul;41(7):1516-25.Texto completo  Resumo

31. Dandona P, Dhindsa S, Ghanim H. Hypogonadotropic hypogonadism in diabesity: pathogenic factors and therapeutic implications. Androg Clin Res Ther. 2022 Dec 28;3(1):214-6.Texto completo  Resumo

32. Rochira V, Kara E, Carani C. The endocrine role of estrogens on human male skeleton. Int J Endocrinol. 2015;2015:165215.Texto completo  Resumo

33. Braunstein GD. Gynecomastia. N Engl J Med. 2007 Sep 20;357(12):1229-37. Resumo

34. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.Texto completo  Resumo

35. Ring J, Welliver C, Parenteau M, et al. The utility of sex hormone-binding globulin in hypogonadism and infertile males. J Urol. 2017 May;197(5):1326-31. Resumo

36. Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. Urology. 2014 May;83(5):980-8. Resumo

37. World Health Organization. WHO laboratory manual for the examination and processing of human semen. Sixth edition. 2021 [internet publication].Texto completo

38. European Association of Urology. EAU guidelines on sexual and reproductive health. 2024 [internet publication].Texto completo

39. Lee H, Hwang EC, Oh CK, et al. Testosterone replacement in men with sexual dysfunction. Cochrane Database Syst Rev. 2024 Jan 15;1(1):CD013071.Texto completo  Resumo

40. Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and aging: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1835-74.Texto completo  Resumo

41. Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017 Nov 16;7(11):e015284.Texto completo  Resumo

42. Wang C, Swerdloff RS. Testosterone replacement therapy in hypogonadal men. Endocrinol Metab Clin North Am. 2022 Mar;51(1):77-98. Resumo

43. Figueiredo MG, Gagliano-Jucá T, Basaria S. Testosterone therapy with subcutaneous injections: a safe, practical, and reasonable option. J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-26.Texto completo  Resumo

44. Fallara G, Pozzi E, Belladelli F, et al. Cardiovascular morbidity and mortality in men - findings from a meta-analysis on the time-related measure of risk of exogenous testosterone. J Sex Med. 2022 Aug;19(8):1243-54. Resumo

45. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014 Oct;13(10):1327-51. Resumo

46. Albert SG, Morley JE. Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clin Endocrinol (Oxf). 2016 Sep;85(3):436-43. Resumo

47. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023 Jul 13;389(2):107-17. Resumo

48. Ayele HT, Brunetti VC, Renoux C, et al. Testosterone replacement therapy and the risk of venous thromboembolism: a systematic review and meta-analysis of randomized controlled trials. Thromb Res. 2021 Mar;199:123-31. Resumo

49. Walker RF, Zakai NA, MacLehose RF, et al. Association of testosterone therapy with risk of venous thromboembolism among men with and without hypogonadism. JAMA Intern Med. 2020 Feb 1;180(2):190-7.Texto completo  Resumo

50. Carson CC 3rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med. 2012 Jan;9(1):54-67. Resumo

51. Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004 Jul;89(7):3313-8.Texto completo  Resumo

52. Hackett G, Cole N, Saghir A, et al. Testosterone replacement therapy: improved sexual desire and erectile function in men with type 2 diabetes following a 30-week randomized placebo-controlled study. Andrology. 2017 Sep;5(5):905-13. Resumo

53. Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):32-45. Resumo

54. US Food and Drug Administration. FDA drug safety communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. February 2018 [internet publication].Texto completo

55. European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. November 2014 [internet publication].Texto completo

56. Jick SS, Hagberg KW. The risk of adverse outcomes in association with use of testosterone products: a cohort study using the UK-based general practice research database. Br J Clin Pharmacol. 2013 Jan;75(1):260-70.Texto completo  Resumo

57. Pastuszak AW, Hu Y, Freid JD. Occurrence of pulmonary oil microembolism after testosterone undecanoate injection: a postmarketing safety analysis. Sex Med. 2020 Jun;8(2):237-42.Texto completo  Resumo

58. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011 Feb;96(2):273-88.Texto completo  Resumo

59. Micko A, Vila G, Höftberger R, et al. Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery. 2019 Oct 1;85(4):508-15. Resumo

60. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e32-41.Texto completo  Resumo

61. Rastrelli G, Corona G, Mannucci E, et al. Factors affecting spermatogenesis upon gonadotropin-replacement therapy: a meta-analytic study. Andrology. 2014 Nov;2(6):794-808.Texto completo  Resumo

62. Lee JA, Ramasamy R. Indications for the use of human chorionic gonadotropic hormone for the management of infertility in hypogonadal men. Transl Androl Urol. 2018 Jul;7(suppl 3):S348-52.Texto completo  Resumo

63. Ide V, Vanderschueren D, Antonio L. Treatment of men with central hypogonadism: alternatives for testosterone replacement therapy. Int J Mol Sci. 2020 Dec 22;22(1):21.Texto completo  Resumo

O uso deste conteúdo está sujeito ao nosso aviso legal